Fox Chase Cancer Center

Site:	Fox Chase Cancer Center	Go to their website
Address:	333 Cottman Ave
City:	Philadelphia
State:	PA
Zip:	19111
Country:	USA

37 trials at this site

Phase	Trial	Trial Status	Site Status	Drug	NCT#
1	A Pilot Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5, Alone or In Combination with Imatinib Mesylate or Sunitinib Malate In Subjects with Advanced Gastrointestinal Stromal Tumors	Withdrawn	Closed	CS-1008 and Imatinib or Sunitinib
3	Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib	Terminated	Closed	IPI-504	NCT00688766
3	Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors (Resistant at 400 mg Imatinib)	Terminated	Closed	Sunitinib or Imatinib	NCT00372567
3	Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor	Terminated	Closed	Imatinib + Bevacizumab	NCT00324987
3	Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients	Terminated	Closed	Imatinib	NCT01031628
2	Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST) (07060)	Terminated	Closed	Nilotinib	NCT00782834
2	Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)	Terminated	Closed	Nilotinib and Imatinib	NCT01089595
1/2	A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies	Recruiting	Active	DCC-3116 + Ripretinib	NCT05957367
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT05208047
2	SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST	Recruiting	Not yet activated	Bezuclastinib plus Sunitinib	NCT06208748
1	A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]	Recruiting	Active	IDRX-42	NCT05489237
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
2	Trial of Dasatinib in Advanced Sarcomas	Ongoing, but not recruiting	Closed	Dasatinib (BMS-354825)	NCT00464620
2	Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01068769
1	Phase 1 Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors	Ongoing, but not recruiting	Closed	Sunitinib + CP-751,871	NCT00729833
1	Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors	Ongoing, but not recruiting	Closed	BIIB022	NCT00555724
1	Safety Study of PLX108-01 in Patients With Solid Tumors	Ongoing, but not recruiting	Closed	PLX3397 (PLX108-01)	NCT01004861
3	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib (ENEST)	Completed	Closed	Nilotinib	NCT00471328
3	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib - Extension	Completed	Closed	Nilotinib	NCT00488150
2	A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing c-Kit Gene (Extension of US Phase II study, B2222)	Completed	Closed	Imatinib	NCT00237185

Fox Chase Cancer Center

37 trials at this site

Page 1 of 2 | Next | Last